Back to discover
Disease
Neoplastic Processes
Clinical development underwayEmerging research
1
Publications
2
Clinical trials
2023
Latest publication
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this disease.
Tumor microenvironment signaling and therapeutics in cancer progression.
Research2023-04-02Cancer communications (London, England)
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Low
Key developments
- 1 clinical trial with recent milestones (1 completed or reporting results).
Clinical MilestonesViewHide
Activity timeline1
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Recent publications
Major themes2
- Neoplasms1
- Tumor Microenvironment1
Leading journals1
- Cancer communications (London, England)1
Leading researchers8
- Ahn BC1
- Dmello CC1
- Gangadaran P1
- Goenka A1
- Jogalekar MP1
- Khan F1
- Sinha P1
- Verma B1
Affiliations (unnormalised)6
- Feinberg School of Medicine1
- Helen Diller Family Comprehensive Cancer Center1
- MassGeneral Institute for Neurodegenerative Disease1
- Schepens Eye Research Institute1
- School of Medicine1
- The Robert H. Lurie Comprehensive Cancer Center1
Reference
Authoritative identity, definition & identifiers.
Defined in MeSH
The pathological mechanisms and forms taken by tissue during degeneration into a neoplasm and its subsequent activity.
Identifiers
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.